Back to all Press

Matthew Weinberg Writes for International Clinical Trials (ICT) Magazine

August 16, 2013

In this article CEO Matthew Weinberg discusses the downsides to self-auditing good clinical practice and the need smaller, more proactive audits, on the other hand, can provide a more intelligent analysis.



Related Articles

April 23, 2012

CEO Matthew Weinberg Presents at FDA Clinical Trials Hearing

April 23 - The Weinberg Group CEO, Matthew Weinberg, presented today at FDA’s hearing titled “Modernizing the Regulation of Clinical Trials and Approaches to Good Clinical Practice.” Mr. Weinberg...

Read the Full Article

February 11, 2014

Drug Companies Face Stricter Clinical Trial Regulation Worldwide

For more information on The Weinberg Group’s independent clinical auditing services, please contact Jeff Antos at jeff.antos@weinberggroup.com or 202.280.0815.

Read the Full Article
Company News

December 15, 2020

Mydecine Innovations Group Engages ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

DENVER, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research,...

Read the Full Article